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Abstract
Long-term treatment with 6-thioguanine (6-TG) for pediatric acute lymphoblastic leukemia (ALL) is associated with high
rates of hepatic sinusoidal obstruction syndrome (SOS). Nevertheless, current treatment continues to use short-term
applications of 6-TG with only sparse information on toxicity. 6-TG is metabolized by thiopurine methyltransferase (TPMT)
which underlies clinically relevant genetic polymorphism. We analyzed the association between hepatic SOS reported as a
serious adverse event (SAE) and short-term 6-TG application in 3983 pediatric ALL patients treated on trial AIEOP-BFM
ALL 2000 (derivation cohort) and defined the role of TPMT genotype in this relationship. We identified 17 patients (0.43%)
with hepatic SOS, 13 of which with short-term exposure to 6-TG (P < 0.0001). Eight of the 13 patients were heterozygous
for low-activity TPMT variants, resulting in a 22.4-fold (95% confidence interval 7.1–70.7; P ≤ 0.0001) increased risk of
hepatic SOS for heterozygotes in comparison to TPMT wild-type patients. Results were supported by independent
replication analysis. All patients with hepatic SOS after short-term 6-TG recovered and did not demonstrate residual
symptoms. Thus, hepatic SOS is associated with short-term exposure to 6-TG during treatment of pediatric ALL and SOS
risk is increased for patients with low-activity TPMT genotypes.
Introduction
Pediatric acute lymphoblastic leukemia (ALL) patients treated
according to modern treatment protocols can expect to
achieve long-term cure in ~90% of cases, but still a significant
proportion of patients suffers from relapse and therapy-related
toxicities [1, 2]. Thus, the challenge to further improve
treatment for children with ALL addresses not only cure from
leukemia, but also reduction of short-term and long-term
therapy-associated toxicities [3]. This can be achieved by an
optimized potential realization of risk and subsequent treat-
ment adaptation to avoid unwanted events.
The thiopurines 6-mercaptopurine (6-MP) and
6-thioguanine (6-TG) play an essential role in treatment
protocols for ALL. Randomized controlled trials (RCTs)
comparing the efficacy and toxicity of 6-MP with 6-TG in
interim maintenance and maintenance therapy of childhood
ALL have demonstrated dose-dependent high rates (>10%)
of severe hepatotoxic side effects [4–6]. These side
effects have features of sinusoidal obstruction
syndrome (SOS) and are associated with long-term expo-
sure to 6-TG. Hepatic SOS after long-term exposure to
6-TG is often reversible, clinical symptoms are commonly
less severe, and mortality is very low compared to hepatic
SOS in association with hematopoietic stem cell trans-
plantation (HSCT) [6, 7]. Hepatic SOS occurring in asso-
ciation with short-term exposure toward 6-TG has
been repeatedly described, but is rare and less well char-
acterized [4, 5, 8–11].
Hepatic SOS, formerly known as veno-occlusive dis-
ease (VOD), almost exclusively occurs after exposure to
drugs or other toxic stimuli and, in histopathology,
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correlates with central obstruction of liver sinusoids, liver
cell necrosis and hemorrhage [6, 7]. The clinical signs and
symptoms of hepatic SOS include abdominal pain and
swelling, portal hypertension with liver enzyme elevations
and jaundice [6, 7]. A pharmacokinetic study accom-
panying a British RCT established a role for the thio-
purine detoxifying enzyme thiopurine methyltransferase
(TPMT) which underlies phenotypically relevant genetic
polymorphism [12, 13] in the association of 6-TG with
hepatic SOS [14]. However, the latter relationship could
not be confirmed by others [8, 15]. As a consequence of
the increased toxicity observed with exposure to 6-TG for
treatment of ALL, 6-MP remained the standard thiopurine
of choice for maintenance treatment of ALL. Since dis-
continuation of long-term 6-TG application, the pre-
viously associated hepatic complications are only rarely
observed during treatment for ALL. Nevertheless, due to
its anti-leukemic potency, currently the majority of clin-
ical protocols for ALL continue to use short-term appli-
cations of 6-TG during intensification elements.
Therefore, we analyzed the reported frequencies and
characteristics of hepatic SOS in a large multicenter
Berlin–Frankfurt–Münster (BFM) RCT on treatment of
pediatric ALL in which 6-TG was applied for 2-week
intervals during late-intensification therapy.
Materials/subjects and methods
Study individuals
From August 1, 2000, to May 31, 2010, a total of 3983 ALL
patients between 1 and 18 years of age were diagnosed in
one of the participating study centers in Germany and
registered in trial AIEOP-BFM ALL 2000 [16–18] (Sup-
plementary Fig. 1). Treatment in this trial, which we used as
derivation cohort, contained standard multidrug che-
motherapeutic regimens (for details see Fig. 1 and Supple-
mentary Table 1) and, in parts of the patient population,
cranial irradiation and/or HSCT. 6-TG (60 mg/m2/d) was
applied for 2 weeks in the second phase of two late-
intensification elements, the so-called Protocol II and Pro-
tocol III (Fig. 1, Supplementary Table 1). Out of the 3983
patients, 813 had TPMT genotype information available
(Supplementary Fig. 1). Our replication cohort included
1566 patients between 1 and 18 years of age, diagnosed
with pediatric ALL from June 1, 2010, to December 31,
2016, and treated in the non-experimental arms of trial
AIEOP-BFM ALL 2009 incorporating the late-
intensification element Protocol II [19]. Informed
consent was obtained from all patients and/or their guar-
dians. Both study protocols AIEOP-BFM ALL 2000 and
Fig. 1 Treatment outline of
AIEOP-BFM ALL 2000.
Details of treatment elements are
listed in Supplementary Table 1.
Results of the randomizations
(R) and data on allogeneic
hematopoietic stem cell
transplantation (HSCT) have
been published before [16, 27].
SR indicates standard risk; MR,
intermediate risk; HR, high risk;
closed boxes indicate treatment
elements: IA, Protocol I phase A;
D+ indicates induction with
dexamethasone and P+ with
prednisone; IB, Protocol I phase
B; M, Protocol M; II, Protocol
II; III, Protocol III; HR1′, HR2′
and HR3′ are intensive high-risk
treatment blocks; 6-MP/MTX,
interim maintenance or
maintenance therapy with 6-
mercaptopurine and
methotrexate; CR cranial
irradiation; closed red boxes
indicate the treatment elements
in which hepatic SOS cases were
observed. The asterisk indicates
the second episode of hepatic
SOS in patient 16 (Table 2)
(color figure online).
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AIEOP-BFM ALL 2009 were approved by the competent
ethics committees and trials were registered at http://clinica
ltrials.gov (NCT00430118 and NCT01117441).
Cases of hepatic SOS were identified through searching the
AIEOP-BFM ALL 2000 and AIEOP-BFM ALL 2009 serious
adverse event (SAE) databases. An SAE was defined as any
untoward medical occurrence that (1) resulted in death; (2)
was life threatening (defined as an event in which the patient
was at risk of death at the time of the event; it did not refer to
an event which hypothetically might have caused death if it
would have been more severe); (3) required or prolonged
hospitalization; (4) resulted in persistent or significant dis-
ability/incapacity; (5) was a congenital anomaly/birth defect
in the offspring. Hepatic SOS was characterized according to
the Ponte di Legno (PdL) diagnostic criteria for SOS in
children with ALL [3] (Supplementary Table 2) and the
European Society for Blood and Marrow Transplantation
diagnostic criteria for hepatic SOS/VOD in pediatric patients
[7]. Patients developing hepatic SOS in association with
HSCT were not included in this study.
TPMT genotyping
DNA extraction from fresh mononuclear cells was per-
formed as described previously [20]. Genotyping for TPMT
was performed by standard RQ-PCR-based genotyping for
the variant TPMT*2 and TPMT*3 alleles, which are asso-
ciated with low TPMT activity [21].
Statistical analysis
Differences in the distribution of categorical variables
were analyzed by chi-squared or Fisher’s exact tests. The
McNemar’s test was used on paired dichotomous data. We
estimated the odds ratios (derivative cohort) or relative risks
(replication cohort) for and calculated their associated 95%
confidence intervals [22]. We report exact p values. The
SPSS (SPSS Inc., Chicago, IL) and SAS (SAS-PC, Version
9.1, Cary, NC: SAS Institute Inc.) statistical packages were
used for the analyses.
Results
We identified 17 patients (0.43%) with hepatic SOS
reported as an SAE out of 3983 patients in the derivation
cohort (AIEOP-BFM ALL 2000) (see Supplementary Fig. 1
for the analytical workflow of this study). No significant
differences with regard to the distribution of important
clinical characteristics related to pediatric ALL were
detected between patients with reported hepatic SOS in
comparison to those without this treatment complication
(Table 1). Four patients developed hepatic SOS during
Table 1 Characteristics of 17 patients with hepatic sinusoidal
obstruction syndrome (SOS) reported as a severe adverse event
during treatment for acute lymphoblastic leukemia (ALL) in












Male 12 (70.6) 2193 (55.3)
Female 5 (29.4) 1773 (44.7) 0.231
Age at diagnosis (years)
<10 14 (82.4) 2946 (74.3)
≥10 3 (17.6) 1020 (25.7) 0.584
Initial WBCb (109/l)
<50 13 (76.5) 3139 (79.2)
≥50 4 (23.5) 825 (20.8) 0.766
n.a. - 2 (0.1)
Immunophenotype
B-cell precursor 17 (100) 3305 (85.2)
T-cell precursor – 555 (14.3)
other – 19 (0.5) 0.223
n.a. – 87 (2.2)
CNS diseasec
No 15 (88.2) 3584 (90.4)
Yes 1 (5.9) 135 (3.4) 0.448
n.a. 1 (5.9) 247 (6.2)
ETV6-RUNX1 rearrangement
Negative 13 (76.5) 2883 (72.7)
Positive 4 (23.5) 839 (21.2) 0.999
n.a. – 244 (6.2)
Prednisone responsed
Good 16 (94.1) 3539 (89.2)
Poor 1 (5.9) 394 (9.9) 0.999
n.a. – 33 (0.8)
Risk groupe
SR 6 (35.3) 1305 (32.9)
MR 8 (47.1) 2050 (51.7)
HR 3 (17.6) 609 (15.4)
Other – 2 (0.1) 0.845
TPMT
wild-type 8 (35.3) 755 (19.0)
Heterozygous 9 (47.1) 54 (1.4)
Deficient – 4 (0.1) <0.0001
n.a. – 3153 (79.5)
aP χ2 or Fisher’s exact test.
bWBC white blood cell count.
cCNS positive: puncture nontraumatic, >5 WBC/μL cerebrospinal fluid
with identifiable blasts
dGood: <1000 leukemic blood blasts/µl on treatment day 8, poor:
≥1000/µl.
eRisk group stratification included minimal residual disease
(MRD) analysis and required two MRD targets with sensitivities
of ≤1 × 10−4, SR patients were MRD-negative on treatment days 33
and 78, HR patients had residual disease of ≥5 × 10−4 on treatment
day 78, all the remaining MRD results were stratified into the
MR group, further HR criteria were prednisone poor response
or ≥5% leukemic blasts in the bone marrow on day 33 or positivity
for t(4;11) or its molecular equivalent (MLL-AF4 gene fusion);
were stratified into the high-risk group independent of their MRD
results.
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induction treatment with a glucocorticoid, vincristine,
L-asparaginase, daunorubicin, and intrathecal methotrexate,
two of them in association with either acute pancreatitis or
severe sepsis (Fig. 1 and Table 2; for treatment details see
Supplementary Table 1). In 13 patients, hepatic SOS
strongly clustered with short-term exposure to 6-TG during
the second phase of late-intensification elements—ten
patients were observed in late-intensification Protocol II and
three patients during Protocol III (Fig. 1 and Table 2). One
patient developed a second episode of hepatic SOS after re-
challenge with 6-TG in a second application of Protocol III.
The difference of frequencies of hepatic SOS in 6-TG-
containing elements compared to other treatment elements
was highly significant (P ≤ 0.0001). All cases associated
with 6-TG exposure were of moderate grade according to
PdL criteria [3]. With one exception, all patients received
defibrotide (Table 2). All patients with 6-TG-associated
hepatic SOS recovered, did not demonstrate residual
symptoms such as portal hypertension/splenomegaly or
nodular regenerative hyperplasia on follow-up, and are in
continuous complete remission (Table 2).
The numbers of patients exposed to 6-TG in trial AIEOP-
BFM ALL 2000 were 2531 for Protocol II and 1212 for
Protocol III. This results in a rate of hepatic SOS in asso-
ciation with 6-TG of 0.40% in Protocol II compared to
0.25% in Protocol III (P= 0.47). Co-medication with 6-TG
in these two late-intensification elements consisted of
similar applications of cytarabine and intrathecal metho-
trexate, while a single cyclophosphamide application was
given at 1000 mg/m2 in Protocol II compared to 500 mg/m2
in Protocol III (Supplementary Table 1). Thus, we could not
evaluate if cyclophosphamide modifies the risk of hepatic
SOS in association with 6-TG treatment.
Next, we compared a representative subset of 813
AIEOP-BFM ALL 2000 patients [20] with available TPMT
genotype data and no reported history of hepatic SOS to the
13 patients with hepatic SOS under exposure to 6-TG
during late-intensification treatment (Protocol II/Protocol
III). Eight (61.5%) of the 13 patients with hepatic SOS were
heterozygous for TPMT variants conferring low enzyme
activity compared to 54 (6.6%) in the cohort without
reported hepatic SOS (Table 1 and Fig. 1). In contrast, only
one out the four patients with hepatic SOS during induction
treatment carried a low-activity TPMT allele (Table 2). The
odds ratio for hepatic SOS under exposure to 6-TG was
22.4 (95% confidence interval 7.1–70.7; P ≤ 0.0001) for
TPMT heterozygotes in comparison to TPMT wild-type
patients. To replicate this association, we analyzed 1566
patients treated on the non-experimental arm of trial
AIEOP-BFM ALL 2009. These patients received the same
6-TG containing Protocol II as given in the previous trial
AIEOP-BFM ALL 2000. A search of the AIEOP-BFM
ALL 2009 SAE database for study individuals with reported
hepatic SOS associated with Protocoll II identified nine out
of 1566 ALL patients (0.57%) (Supplementary Table 3).
Three of the nine patients were heterozygous for TPMT
alleles conferring low enzyme activity (all TPMT*1/*3A)
resulting in a 6.73-fold increased relative risk (95% con-
fidence interval 1.71–26.53; P= 0.007) of hepatic SOS in
association with 6-TG for heterozygotes in comparison to
TPMT wild-type patients.
Discussion
In the present analysis, short-term exposure to 6-TG during
treatment for pediatric ALL was associated with hepatic SOS
and patients with TPMT genotypes conferring low enzyme
activity were at increased risk. Supporting the specificity of
the association of hepatic SOS with 6-TG exposure, no
patient with hepatic SOS in association with the second phase
of Protocol I was detected. This treatment element equals the
second phases of Protocol II and Protocol III except that 6-
MP is applied instead of 6-TG (Supplementary Table 1).
Therefore, in a similar treatment context, hepatic SOS recor-
ded as an SAE was only observed in context with application
of 6-TG, but virtually absent with 6-MP. The latter observa-
tion suggests that replacement of 6-TG by 6-MP in late-
intensification elements may abolish or at least significantly
reduce the appearance of hepatic SOS during late-
intensification. Due to the currently observed good long-
term outcome of our patients with hepatic SOS in association
with short-term 6-TG and the lack of data on equivalent anti-
leukemic efficacy of 6-MP versus 6-TG in late-intensification
elements we did not yet change the drug compositions of
Protocols II and III. However, we alert clinicians to the spe-
cific risk of hepatic SOS under exposure to 6-TG in our
clinical protocols. A potential explanation for the differential
impact of 6-TG and 6-MP on risk of hepatic SOS may be
specific angioprotective properties attributed to 6-MP. In
different vascular disease model systems, 6-MP was shown to
impact on the expression of adhesion molecules, to reduce
monocyte attraction/adhesion, to induce monocyte apoptosis,
to inhibit re-stenosis and to attenuate inflammation, while
stimulating endothelial coverage [23–26].
In a single institution study, McAtee et al. recently
published a series of ten (1.5%) hepatic SOS out of 680
pediatric ALL patients treated at Texas Children’s Cancer
Center [9]. Compared to long-term exposure during 6-TG-
based maintenance treatment of ALL, hepatic SOS in
context of short-term 6-TG exposure was associated with
earlier onset and higher mortality (20%) which led the
authors to conclude that hepatic SOS after short-term 6-TG
treatment may be a clinically distinct phenotype with
similarities to hepatic SOS in association with HSCT.
Regarding timing of hepatic SOS our data confirm the
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observation of McAtee et al. of an early onset in close
association with 6-TG application (Table 2) [9]. Similarly,
we also observed a high frequency of low TPMT activity in
our patients. This may support the hypothesis that altered 6-
TG metabolism may either modify the severity of hepatic
SOS or—as associations with long-term exposure are con-
tradictory—reflect a stronger effect of variant TPMT in
association with short-term exposure during late intensifi-
cation. In addition, our data provide a further instructive
example for the importance to subject pediatric ALL
patients treated with thiopurines to TPMT genotyping.
Intriguingly, McAtee et al. described confirmed or sus-
pected infections prior to diagnosis of hepatic SOS in six
out of ten cases with hepatic SOS [9]. Due to unavailability
of data, we cannot reliably evaluate this association in our
study. The single patient in our study suffering from con-
comitant sepsis who finally died in association with hepatic
SOS was observed during induction treatment and not in
association with 6-TG. Although also potential differences
in protocol-specific treatment exposures may have con-
tributed here, the lower frequency of hepatic SOS in our
study compared to McAtee’s study is likely due to the
inclusion of hepatic SOS reported as an SAE, only. This
indicates that we probably did not capture all/less severe
episodes of hepatic SOS. Therefore, careful monitoring for
signs of hepatic SOS in association with short-term 6-TG
exposure in future studies will have to characterize the
entire clinical spectrum and determine the true incidence of
this complication.
We conclude that hepatic SOS reported as an SAE on
contemporary ALL-BFM trials cluster with short-term
application of 6-TG during late-intensification elements
and are associated with TPMT genotype. Particularly for
TPMT heterozygotes, replacement of 6-TG by 6-MP may be
an effective measure to reduce the incidence of hepatic SOS
during treatment for pediatric ALL.
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